A synthetic analog of growth hormone-releasing hormone (GHRH 1-29) previously FDA-approved for diagnosing and treating growth hormone deficiency in children.
Anorexia nervosa is associated with several abnormalities in GH secretion elicited by different stimuli. To investigate the precise mechanism of this alteration, GHRH was administered to 14 women: a group of eight anorexia nervosa patients in the acu…
The aim of this study was to determine the effect of age and sex on basal secretory patterns of growth hormone (GH) and growth hormone-releasing factor (GRF) induced GH release. Eighteen pigs (9 castrated males and 9 females) were stimulated with pGR…
Sixteen male Holstein calves averaging 168 kg body weight (BW) were used to determine the effects of human growth hormone-releasing factor (1-29)NH2 (hGRF (1-29)NH2; .22 micrograms/kg BW), thyrotropin-releasing factor (TRF; .165 micrograms/kg BW) or…
A good response after an intravenous bolus of GRF-1-29 NH2 in patients with hypopituitary dwarfism localities the site of the GH-deficiency in the hypothalamus (GRF deficiency). These patients could be treated with GH and GRF. Never the less some pat…
This study was undertaken to evaluate the biological potency of two synthetic human growth hormone-releasing factors, hGRF (1-44)NH2 and hGRF (1-29)NH2, on growth hormone (GH) release in young dairy heifers (n = 10) and pigs (n = 10). In each species…
The ability of human (h)GRF-(1-29)NH2 to stimulate GH secretion was studied in cannulated adult rats. In order to suppress endogenous GRF secretion and the inhibitory action of hypothalamic somatostatin (SRIF), rats were anesthetized with sodium pent…
The solution conformation of the 27 residue polypeptide hormone secretin has been investigated by 1H-NMR spectroscopy under conditions where it adopts a fully ordered structure as judged by circular dichroism spectroscopy, namely in an aqueous soluti…
It is well established that compounds that modify dopaminergic and cholinergic activity in man may induce changes in circulating growth hormone (GH). We have, therefore, investigated the effect of a dopamine agonist, bromocriptine, and a dopamine ant…
A stimulation test using 1 microgram growth-hormone-releasing factor (GRF 1-29 X NH2)/kg bodyweight was performed in children with familial short stature and in children with constitutional delay of growth and development. The GH secretion induced by…
18 prepubertal growth-hormone (GH)-deficient children were treated with twice-daily subcutaneous injections of a growth-hormone-releasing hormone analogue, GHRH (1-29) NH2. In 12 of the children the height velocity rose on GHRH treatment, and 8 were…
Plasma somatotropin (GH) and somatomedin C (IGF1) concentrations were measured by radioimmunoassay in 3-dy old and 10-day old calves intravenously injected with growth hormone releasing factor (GRF) 1-44, GRF 1-29 or thyrotropin-releasing hormone (TR…
The secretion of hGH after the administration of the analogue of growth hormone releasing hormone, GHRH (1-29)NH2, to 8 normal adults and 41 short children has been studied. The children were classified on the basis of their hGH response to insulin-i…
The excellent retention of biological potencies observed with human growth hormone releasing factor analogues with chains 29-44 amino acid residues long is suddenly lost when further amino acid residues are removed from the C-terminus. For instance,…
The growth promoting potential of GRF(1-29)NH2 was studied in nine boys with short stature over three periods of 3 months. Their short stature was due to partial hGH deficiency/hGH neurosecretory dysfunction and was diagnosed by arginine and insulin…
Calcitonin (CT) binds to specific receptors in the hypothalamus and has been localized in the pituitary, suggesting a potential neuroendocrine role for this peptide. We and others have previously shown that CT given centrally markedly suppresses puls…
1. The administration of 125I-labelled growth hormone-releasing factor (GRF) analogue 1-29NH2 by intravenous, subcutaneous or intraperitoneal injection to rats leads to rapid (i.v.) or slow (s.c. and i.p.) increases in plasma radioactivity followed b…
Human growth hormone releasing hormone (GRF 1-44 or GRF 1-29) was administered to lambs at two different physiological stages (suckling: 5-6 week-old and weaned: 14-15 week-old) when growth hormone (GH) secretory patterns were different: suckling lam…
We have recently reported an impaired growth hormone (GH) response to a single i.v. bolus dose of growth hormone releasing factor (1 microgram/kg body weight) in obese women. We have now investigated whether the i.v. administration of low dose GHRF(1…